The initial interaction of chlamydiae with host cells is not well understood. Chlamydial cell surface components that function in attachment are key virulence factors, and their identification is critical for understanding the pathogenic strategies of this very successful parasite. We used trypsin proteolysis of chlamydiae to define surface components that function in chlamydia-host cell interactions. We found that trypsin had a differential effect on the infectivity of Chlamydia trachomatis serovars B and L2 for HeLa 229 cells. Trypsin treatment resulted in a significant loss of attachment and infectivity of serovar B but had no effect on the infectivity of serovar L2. Fluorograms of chlamydiae metabolically labeled with '4C-amino acids and treated with trypsin showed that the major outer membrane protein (MOMP) of both serovars was cleaved. Evidence for two trypsin cleavage sites was found for the serovar B MOMP. One cleavage site was located between lysine 145 and valine 146 in variable domain (VD) II of the protein. The second site was located between lysine 309 and threonine 310 in VD IV. In contrast, the serovar L2 MOMP was cleaved only at lysine 309 in VD IV. These results suggest a functional role for MOMP in chlamydial attachment and implicate VDs II and IV of MOMP in this interaction.
Chlamydia trachomatis is an obligate intracellular bacterium that infects mucosal epithelial cells of humans, causing blinding trachoma and sexually transmitted urogenital diseases (8) . These diseases afflict millions throughout the world each year and are major public health problems for which control and prevention measures are clearly needed.
Chlamydiae are distinguished from other intracellular procaryotes by their complex life cycle. They exist as two distinct developmental forms which differ both morphologically and functionally. The structurally rigid elementary body (EB), which is 200 nm in diameter, is the infectious form of the parasite. It survives extracellularly and attaches to and enters host cells (13, 14) . After entry, the EB resides within a host phagosome and quickly differentiates into a larger (1,000 nm in diameter) noninfectious reticulate body. The fragile reticulate body is metabolically active and divides by binary fission within the endosome. The replicated reticulate bodies then differentiate to become infectious EBs that are released from the infected cell and reinitiate the infectious process. The surface components that function in the attachment of chlamydiae to host cells are clearly key virulence factors. Their identification and molecular characterization are crucial in our understanding of chlamydial pathogenesis and in developing a chlamydial vaccine.
The predominant protein species found in the chlamydial outer membrane is the ca. 40,000-molecular-weight major outer membrane protein (MOMP) (40K MOMP). It plays an important role in maintaining the structural integrity of the outer membrane of the infectious EB through intra-and intermolecular disulfide bonds (la, [10] [11] [12] more common antigenic determinants that confer subspecies-, serogroup-, and species-specific determinants (3, 18) . All serovar-specific MOMP epitopes and some serogroupspecific MOMP epitopes are highly immunoaccessible at the EB cell surface and are immunodominant epitopes recognized during chlamydial infection (18) . Monoclonal antibodies (MAbs) specific for these MOMP epitopes passively neutralize chlamydial toxicity and infectivity in vivo but do not neutralize the in vitro infectivity of the organism for HeLa 229 cells (7) . These differences between in vivo and in vitro neutralization results are not understood. In addition, the mechanism by which MOMP MAbs neutralize infectivity in vivo is unknown. MAbs specific to a surface-accessible epitope on chlamydial lipopolysaccharide do not neutralize infectivity in vivo, demonstrating that accessibility of surface antigens to antibody per se is insufficient for in vivo neutralization of chlamydial infectivity. We have interpreted these findings as evidence that implicates the MOMP in the pathogenesis of chlamydial infection.
Recently, the MOMP genes of C. trachomatis serovars L2 and B have been sequenced (1, 15) . These genes encode amino acid sequences that are approximately 93% homologous. Nonhomologous amino acids reside within four variable domains (VDs). Three of these (VDs I, II, and IV) protrude toward the external environment at the chlamydial cell surface and are major antigenic sites whose structures have been defined (1, i5a the interaction of chlamydiae with host cells. We present evidence that strongly supports a role for MOMP in the attachment of this parasite to its eucaryotic host cell.
MATERIALS AND METHODS
Chlamydiae. C. trachomatis serovar B (strain TW-5/OT) and serovar L2 (strain LGV/434/Bu) were propagated in HeLa 229 cells. EBs were purified from infected cells by Renografin density gradient centrifugation (5) . Chlamydiae were metabolically radiolabeled with 14C-amino acids as previously described (6) .
Monoclonal antibodies. The production of hybridomas secreting MAbs and the characterization of these MAbs have been described in previous studies (3, 18) , and a summary of the properties of these MAbs is shown in Table   1 .
Trypsin treatment of chlamydiae. (i) Infectivity assays. cells) grown on glass cover slips. After 2 h of absorption at 37°C, the inoculum was removed and fresh medium was added to the cells. Cells were incubated for 48 h at 37°C and then were processed for the determination of IFU as previously described (10).
(ii) Attachment assays. A 1.0-ml volume of 14C-labeled serovar B EBs (6.3 x 107 IFU [3.1 x 106 cpm/ml]) was treated with 1 ,ug of trypsin at 37°C for 120 min. Control organisms were incubated in 0.25 M sucrose-10 mM sodium phosphate-5 mM L-glutamic acid (pH 7.2) buffer alone. The suspensions were diluted in 0.25 M sucrose-10 mM sodium phosphate-5 mM L-glutamic acid (pH 7.2) to give a final concentration of 6.3 x 106 IFU (3.1 x 105 cpm/ml). Two hundred microliters of the suspension was inoculated onto each of four HeLa 229 cell monolayers, and the cells were incubated at 37°C for 2 h. The inoculum was removed, and the monolayers were washed three times with 500 ,ul of Hanks balanced salt solution. Two monolayer cultures were fed with minimal essential medium 10 and incubated at 37°C for 72 h and processed to determine IFU. The remaining two monolayers were lysed with 200 ,ul of 0.1 N NaOH at 70°C for 1 h. The solubilized cells were collected, and the wells were washed twice with 200 ,ul of 0.1 N NaOH. Lysates and their corresponding washes were pooled, mixed with 10 ml of liquid scintillation cocktail (Ready-Sov; Beckman Instruments, Inc., Fullerton, Calif.), and the radioactivity associated with each sample was determined with a liquid scintillation counter (LS 9000; Beckman).
The physical properties of trypsin-treated chlamydiae were examined by determining their osmotic stability and isoelectric point. Osmotic stability was determined by measuring the absorbance at 540 nm of trypsin-treated organisms in hypotonic (distilled water) or hypertonic (0.25 M sucrose) solutions. Isoelectric focusing of chlamydiae was done as described by Vance and Hatch (17) .
(iii) Protease accessibility of chlamydial surface proteins. A 100-,ul volume of EBs intrinsically labeled with 14C-amino acids (serovar B, 6.3 x 107 IFU/ml, 6 .1 x 106 cpm/ml; serovar L2, 8.0 x 107 IFU/ml, 9 x 105 cpm/ml) were incubated with 1 ,ug of trypsin for various times at 37°C. Trypsin was inhibited by the addition of 2 mM phenylmethylsulfonyl fluoride. The suspensions were pelleted and suspended in H20 and then mixed with 100 ,ul of Laemmli sample buffer and placed in a boiling water bath for 10 min. A 20-,ul volume of the solubilized suspensions was electrophoresed on a 12.5% polyacrylamide gel. Fluorography of polyacrylamide gels was produced by the procedure of Bonner and Laskey (2). Dot blot and Western blot (immunoblot). Chlamydiae were treated with trypsin as described above, and the immunoreactivity of MOMP was determined by both dot blot and Western blot assays with the group of MAbs described in Table 1 . The methods used for these assays have been described previously (3, 18) . Briefly, organisms were treated with trypsin for various times; the enzyme was then inhibited by the addition of 2 mM phenylmethylsulfonyl fluoride. For the dot blot test, chlamydiae were diluted in phosphatebuffered saline to a concentration of S ,ug of protein per ml. A 50-,ul volume of this suspension was then used in the dot blot assay by the methods previously described (18) . For Western blots, trypsin-treated organisms were pelleted and suspended in Laemmli sample buffer, boiled, and electrophoresed on a 12.5% polyacrylamide slab gel. Western blots of gels were done as previously described (3). Two-dimensional peptide mapping. 125Iodine peptide maps of MOMP and its tryptic peptide fragments were produced as described by Swanson (4, 16) , with the following modifications. Precoated thin-layer chromatography plastic sheets (cellulose) (E. Merck AG, Darmstadt, Federal Republic of Germany) were used. Electrophoresis was done at a constant voltage of 1,200 V for 22 min at 13°C.
RESULTS
The effect of trypsin on chlamydial infectivity. C. trachomatis serovars B and L2 were assayed for infectivity after treatment with 0.1, 1.0, and 10 ,ug of trypsin for various periods of time (Fig. 1) throughout the period of trypsin treatment. However, a different tryptic peptide profile was observed for serovar L2 MOMP. Serovar L2 MOMP was less rapidly degraded by trypsin, and only two proteolytic fragments, 36K and 6K, were detected. The rate of trypsin cleavage differed significantly for each serovar. The cleavage of the majority of serovar B MOMP into the 29K and 16K fragments occurred within 15 to 30 min, whereas cleavage of the majority of serovar L2 MOMP into its two peptide fragments occurred between 60 and 120 min. This suggested that the initial cleavage site on serovar B MOMP was highly accessible to trypsin and that a similarly exposed site may not exist on serovar L2 MOMP. The total molecular mass of the tryptic peptide fragments produced from both MOMPs were nearly equal to that of their respective monomeric MOMPs, indicating that all fragments remained associated with the outer membrane after cleavage.
Two-dimensional peptide mapping of MOMP trypsin fragments. To ascertain the relationships of the four trypsin fragments of serovar B MOMP (29K, 20K, 16K and 6K) to each other and to the intact MOMP, we mapped the peptides of each fragment and of the monomeric MOMP. The peptides generated from chymotrypsin-digested monomeric MOMP (Fig. 3A) were assigned numbers to facilitate their identification in maps of each tryptic fragment. Two-dimensional peptide maps generated from the 20K, 16K, and 6K tryptic fragments showed that together they represent all of the peptides found in the monomeric MOMP. The peptides found in the 20K and 6K fragments were also present in the map of the 29K tryptic fragment, demonstrating that these two fragments were derived from the larger 29K polypeptide. These data and those shown in Fig. 2 suggested that at the cell surface, serovar B MOMP was cleaved at two different locations. The initial rapid cleavage produced polypeptides 29K and 16K. The 29K fragment was then further cleaved to produce fragments of 20K and 6K. In contrast, the serovar L2 MOMP appeared to have a single trypsinaccessible site which was cleaved to produce 36K and 6K fragments.
Antigenicity of MOMP tryptic fragments. To identify the trypsin cleavage sites on the serovar B and L2 MOMPs, we used previously characterized MAbs to determine the antigenicity of each proteolytic fragment (Table 1) . MAbs B-B6 and L2I-45 are specific to serovars B and L2, respectively, and bind to epitopes located in VD II (Baehr et al., in press; Stephens et al., in press). MAb B-B5 is subspecies specific (to serovars B, Ba, and D) and reacts with an epitope located in VD IV of serovar B MOMP. All of these determinants are accessible to antibodies on the native chlamydial cell surface. MAb L21-10 binds to a highly conserved speciesspecific epitope located in VD IV. This epitope is not accessible to antibodies on the surfaces of serovars B and L2.
The effect of trypsin on the antigenicity of B-B6, B-B5, and L21-10 epitopes of the serovar B MOMP was determined by dot blot and Western blot analysis (Fig. 4) . The dot blots showed the effect of trypsin on the antigenicity of MOMP at the EB cell surface. The Western blots demonstrated the antigenic properties of polypeptides derived from trypsin cleavage of MOMP at the cell surface. The dot blots showed that both epitopes, B-B6 and B-B5, were destroyed by trypsin at the chlamydial cell surface. Epitope B-B6 was destroyed more rapidly than epitope B-B5. Interestingly, the loss of B-B6 and B-B5 antigenicity was accompanied by the surface exposure of the conserved species-specific L21-10 determinant. The antigenicity of the L2I-10 determinant was trypsin resistant.
The immunoreactivity of serovar B MOMP tryptic peptides with the same panel of MAbs is shown by the Western blots in Fig. 4B . Peptides 29K, 20K, 16K, and 6K were produced from MOMP after trypsin treatment of serovar B EBs (Fig. 2) . The 16K and 6K tryptic MOMP fragments did not react with any of the MAbs. (Fig. 2) were not immunoreactive.
enough of the critical amino acids remained in this peptide to result in low-avidity binding by MAb B-B6. MAb B-B5 reacted with both the monomeric MOMP and the 29K intermediate fragment; however, cleavage of the 29K fragment into the 20K and 6K peptides resulted in a loss of reactivity with MAb B-B5. MAb L21-10 reacted with the monomeric MOMP and the 29K and 20K fragments, and its reactivity with the 20K fragment was trypsin resistant. These findings showed that serovar B MOMP was cleaved in both VD II and VD IV by trypsin. The trypsin site located in VD II was within the B-B6 epitope and was rapidly cleaved by trypsin. The trypsin site located in VD IV was within the B-B5 epitope but was not within the L21-10 epitope, and it was not cleaved as rapidly as the site within VD II.
A different result was observed with trypsin-treated serovar L2 EBs (Fig. 5) . The dot blot reactivity of MAb L21-45, which recognizes the surface-accessible, serovar-specific epitope located in VD II of serovar L2 MOMP, was not affected by trypsin. Like L21-10 after trypsin treatment. Western blots of serovar L2 MOMP tryptic fragments showed that the 36K fragment reacted with both MAbs L21-45 and L21-10. The 6K fragment (Fig. 2) was not immunoreactive. These findings indicated that trypsin does not cleave the serovar L2 MOMP in VD II but cleaves only in VD IV, resulting in fragments of 36K and 6K. Therefore, the only difference in cleavage of serovar B and L2 MOMPs by trypsin was within VD II. A small amount of a fragment of 25K was observed after 60 min of digestion. This fragment reflects additional cleavage of MOMP in or near VD IV.
DISCUSSION
In this study, we examined the effect of trypsin proteolysis of viable chlamydiae on their binding to and infection of HeLa 229 cells. Trypsin substantially reduced binding affinity and infectivity of serovar B EBs for HeLa cells but had no effect on serovar L2 EBs. By using trypsin and a panel of previously characterized MAbs, we identified surface-exposed domains of the MOMP which may be involved in interactions of chlamydiae with host cells. MOMP VDs II and IV are critical for chlamydial infectivity, and these structures, either separately or cooperatively, play a role in the attachment of chlamydiae to host cells. A model of serovar B and L2 MOMP trypsin cleavage sites at the cell surface is presented in Fig. 6 . The primary amino acid sequences of serovar B and L2 MOMPs in VDs II and IV are depicted in Fig. 6A ; both the potential trypsin cleavage sites and the MAb binding sites are illustrated. The schematic shown in Fig. 6B summarizes the cleavage sites of the MOMPs, the kinetics of proteolysis, and the resulting tryptic fragments. The serovar B MOMP was cleaved twice by trypsin; the first cleavage was complete within 15 to 30 min and occurred in VD II between lysine 145 and valine 146. This destroyed the B-B6 epitope and generated the 29K and 16K peptide fragments. The 29K fragment was then cleaved in VD IV between lysine 309 and threonine 310. This second cleavage occurred more slowly, destroyed the B-B5 epitope, and generated peptide fragments 20K and 6K. In contrast, the serovar L2 MOMP was cleaved once at lysine 309 in VD IV, generating fragments 36K and 6K. The trypsin site at lysine 150 in VD II of serovar L2 MOMP was not cleaved by trypsin. Either it was inaccessible to the enzyme or the local microenvironment reduced trypsin activity. Cleavage within VD IV of both MOMPs resulted in accessibility of the conserved species-specific L2I-10 epitope to antibody. The L2I-10 epitope was resistant to trypsin as it was used in these experiments.
The kinetics of loss of infectivity of serovar B EBs (Fig. 1 ) correlate with the kinetics of trypsin cleavage (Fig. 2) in VD IV. The total cleavage of VD 11 (30 min) does not correspond to maximal loss in infectivity. Maximal reduction in infectivity occurred when both VD II and VD IV were cleaved by trypsin. There are several possible explanations for this effect: (i) cleavage of both domains sufficiently alters the tertiary or quaternary structure of MOMP and prevents the appropriate binding domains from interacting with the host cells; (ii) VD II and VD IV form a combined binding site, and cleavage in both domains is required to alter binding; and (iii) only one domain (i.e., VD II) may be involved in actual binding to host cells; however, the other domain may be essential to maintain conformational integrity through disulfide cross-linking or side chain interactions with this domain.
Conformational changes in MOMP do occur, as demonstrated by the binding of MAb L2I-10 to the cell surface after trypsin treatment (Fig. 3A) . This MAb does not bind to native chlamydiae; however, following trypsin treatment, this epitope becomes immunoaccessible in both serovars. The L21-10 epitope is located within amino acids 296 and 304 and is 4 amino acid residues toward the amino terminal from the trypsin cleavage site in VD IV.
The MAbs that bind to the trypsin-sensitive epitopes in MOMP VDs II and IV did not neutralize infectivity of chlamydiae for HeLa 229 cells. In contrast, these MAbs do neutralize infectivity in vivo (7) . This apparent paradox has been difficult to understand. Because these MAbs neutralize infectivity in vivo, the failure to neutralize infectivity in vitro may be a property of HeLa cells and not the antibodies. It is possible that HeLa cells possess receptors for an immunoglobulin(s), and thus, through endocytosis, antibody-bound chlamydiae may infect the cell via these receptors. Such a mechanism would circumvent normal chlamydial-host cell mechanisms of attachment and uptake but may provide an equally functional environment for chlamydial growth. Thus, two mechanisms may exist for attachment of chlamydiae to HeLa cells. One is through binding of chlamydial MOMP to a HeLa cell receptor, and the other occurs in the presence of chlamydia-specific antibodies and may be mediated by immunoglobulin receptors on HeLa cells.
A variety of proteases are present at mucosal surfaces and would theoretically be capable of cleaving sensitive sites within the immunodominant VDs of MOMP. Depending upon the sequence and structure of the serovar-specific epitopes, some serovars may be more susceptible than others to proteolytic cleavage. If cleavage occurs, the immunogenicity of the MOMP could be altered, resulting in the loss of protective immune responses directed at type-specific epitopes. This may allow chlamydiae to escape clearance by the immune response. In addition, individuals infected with serovars whose MOMP serovar-specific epitopes are protease sensitive may not produce antibodies directed at these epitopes. Therefore, serologic profiles of these individuals The MOMP genes from all serovars for which these proteins have been sequenced have potential trypsin cleavage sites within either VD I or VD II. Protective typespecific epitopes have not been defined for all serovars. Identification and characterization of protective type-specific epitopes and of MOMP-binding domains of other serovars should lead to greater understanding of the immune response to MOMP and of the role of MOMP in attachment to host cells.
Previously, Hackstadt and Caldwell (9) reported that MOMP did not have a role in the binding of chlamydiae to host cells. This conclusion was reached following similar experiments in which serovar L2 MOMP was extensively digested with trypsin without effect on the infectivity of the organisms for HeLa 229 cells. Both studies showed that trypsin treatment had no effect on the infectivity of serovar L2 and that immunoreactivity with MAb L21-45 was maintained at the cell surface after trypsin digestion. The major difference observed between the two studies is the sensitivity of the L21-10 epitope to trypsin. This difference can be explained at least in part by comparing the proteolysis conditions used in each of the experiments. In our initial study, a trypsin/chlamydia ratio of 0.4:1 (wt/wt) was used. These conditions resulted in a more extensive digestion of serovar L2 MOMP, which generated four small immunoreactive fragments that were detected with a monospecific polyclonal antiserum raised against purified serovar L2 MOMP. In this study, at a trypsin/chlamydia ratio of 0.04:1 (wt/wt), two MOMP fragments were generated which together accounted for the entire MOMP molecule. We believe that these differences can be explained by the additional cleavage of MOMP at lysine 287 by using higher concentrations of trypsin. This residue occurs in the sequence at the start of VD IV and is 8 amino acid residues before the start of the L21-10 epitope. If MOMP were cleaved with trypsin at this site and at the already identified site in VD IV (lysine 309), the entire L21-10 epitope would be cleaved from the protein. It is likely that this fragment would be totally lost from the cell surface, as it lacks cysteine residues by which disulfide crosslinking would have enabled the small fragment to remain attached to MOMP at the cell surface. Therefore, we now conclude that MOMP may play a role in binding to host cells. The most conclusive evidence for this comes from data accumulated by studying serovar B and comparing these findings with those obtained from studies of serovar L2.
The data presented in this paper suggest that chlamydial MOMP functions in the attachment of chlamydiae to host cells; however, conclusive evidence for the role of MOMP can only be obtained by using purified MOMP which has maintained its native conformation. Because it is unlikely that such a preparation of MOMP will ever be isolated, we are using recombinant and synthetic peptides of the various variable domains of serovar B and L2 MOMPs to further investigate the role of MOMP in binding and attachment to host cells.
